Abstract:The Canadian Journal of Psychiatry, Ahead of Print. ObjectivesTo characterize the effects of adjunctive brexpiprazole on patient life engagement and depressive symptoms in patients with major depressive disorder (MDD) using patient-reported outcomes.MethodsAn 8-week, Phase 4, open-label, interventional study was conducted at 15 Canadian trial sites between April 2021 and May 2022. Adult outpatients with MDD (at least moderately severe) and inadequate response to 1–2 antidepressants continued their current antidepressant and received oral adjunctive brexpiprazole 0.5–2 mg/day. Co-primary endpoints were changed from baseline to Week 8 in Inventory of Depressive Symptomatology Self-Report (IDS-SR) 10-item Life Engagement subscale score, and IDS-SR 30-item total score. Safety was assessed by standard variables.ResultsOf 122 enrolled patients, 120 (98.4%) were treated (mean [SD] dose: 1.2 [0.4] mg/day) and analyzed, and 111 (91.0%) completed the study. Statistically significant least squares mean improvements to Week 8 were observed on IDS-SR10 Life Engagement subscale score (baseline mean [SD]: 16.1 [4.7]; change [95% confidence interval]: −8.11 [−9.34, −6.88]; p < 0.001) and IDS-SR total score (baseline mean [SD]: 41.3 [9.8]; change [95% confidence interval]: −17.38 [−20.08, −14.68]; p < 0.001). Improvements were observed from Week 2, onwards. Treatment-emergent adverse events with incidence ≥5% were fatigue (n = 13, 10.8%), headache (n = 13, 10.8%), insomnia (n = 12, 10.0%), nausea (n = 9, 7.5%), tremor (n = 8, 6.7%), and weight increase (n = 7, 5.8%). Six patients (5.0%) discontinued due to adverse events. Mean (SD) change in body weight from baseline to last visit was +1.9 (3.4) kg.ConclusionsUsing an exploratory patient-reported outcome measure, patients with MDD and inadequate response to antidepressants who received open-label adjunctive brexpiprazole showed early and clinically meaningful improvement in patient life engagement, which should be further assessed in a prospective randomized controlled trial. Patient-rated depressive symptoms (on the validated 30-item IDS-SR) also improved. Adjunctive brexpiprazole was well tolerated, and no new safety signals were observed.Clinical Trial RegistrationClinicalTrials.gov identifier: NCT04830215.

Antidepressant Effects of Combination of Brexpiprazole and Fluoxetine on Depression-Like Behavior and Dendritic Changes in Mice after Inflammation

Adjunctive Treatment of Brexpiprazole with Fluoxetine Shows a Rapid Antidepressant Effect in Social Defeat Stress Model: Role of BDNF-TrkB Signaling

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

The effect of fluoxetine hydrochloride in expression of neuropeptide Y of hypothalamus in depression mice model under chronic stress

Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period.

AMPA receptors modulate enhanced dopamine neuronal activity induced by the combined administration of venlafaxine and brexpiprazole

Chronic Fluoxetine Enhances Extinction Therapy for PTSD by Evaluating Brain Glucose Metabolism in Rats: an [18F]FDG PET Study

Progesterone and Fluoxetine treatments of postpartum depressive-like behavior in rat model.

Fluoxetine Protects Against Inflammation and Promotes Autophagy in Mice Model of Post-Traumatic Stress Disorder.

Chronic Fluoxetine Treatment Reverses Depressive-like Behaviors in Mice via Enhancing Neuroplasticity

Antidepressant Effects of TrkB Ligands on Depression-Like Behavior and Dendritic Changes in Mice after Inflammation.

The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain

LPS Inhibits the Effects of Fluoxetine on Depression-Like Behavior and Hippocampal Neurogenesis in Rats.

A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder

Effects of Escitalopram, R-citalopram, and Reboxetine on Serum Levels of Tumor Necrosis Factor-Α, Interleukin-10, and Depression-Like Behavior in Mice after Lipopolysaccharide Administration

Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice

Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study

Anti-inflammatory Effects of Fluoxetine in Lipopolysaccharide(lps)-Stimulated Microglial Cells

The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia

Alleviative Effects of Fluoxetine on Depressive-Like Behaviors by Epigenetic Regulation of BDNF Gene Transcription in Mouse Model of Post-Stroke Depression

Rapid reorganization of serotonin projections and antidepressant response to 5-HT1A-biased agonist NLX-101 in fluoxetine-resistant cF1ko mice